Drugs / TTK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00682227 | Aug 2006 → Dec 2008 | esophageal squamous cell carcinoma | University of Yamanashi | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00682227 ↗ |
| Target | TTK | “We previously identified three novel HLA-A24-restricted epitope peptides, which were derived from three cancer-testis antigens, TTK protein kinase (TTK), lymphocyte antigen 6...” PMID 19459850 ↗ May 2009 |